Acquisition Overview - Terumo Corporation is acquiring OrganOx Limited for $1.5 billion on a cash-free/debt-free basis[2] - The acquisition is expected to close by the end of FY2025 and will be funded with cash on hand and debt[2] OrganOx Details - OrganOx's revenue in 2024 was $71 million[6] - OrganOx has 199 employees as of June 30, 2025[6] Strategic Rationale - The acquisition addresses the unmet need for transplant organs and enters a high-growth industry[8] - The organ preservation opportunity size is estimated at $1.9 billion with a CAGR of more than 10% from 2023-2028[11] OrganOx Technology - OrganOx's metra allows liver preservation for 12 hours in the U.S and 24 hours in Europe[17] - Utilization rate: 37% of transplantable livers from limited donors are not usable (U.S.)[15] Financial Impact - The acquisition is expected to contribute positively to adjusted operating profit[27] - EPS before amortization of intangible assets is expected to contribute positively from FY2026[27]